Here is a re-posting of one of my posts from July 27th 2015 that breaks down what we know about the proposed BETonMACE trial and puts it into the context of the MACE event rates, trial lengths, and patient populations of SUSTAIN and ASSURE.

Warning, it contains some added speculation on what it may mean if BoM is "an event-based trial and will continue until a minimum of 250 primary endpoint events have occurred." (quoted from the July 2015 Annual Information Form).

Have a good weekend,

BDAZ